Skip to main content
. 2014 Nov 28;26(1):117–122. doi: 10.1097/CAD.0000000000000159

Fig. 2.

Fig. 2

Kaplan–Meier curve of overall survival in patients with metastatic breast cancer who received treatment with nab-paclitaxel or conventional paclitaxel as greater than first-line therapy in the randomized Phase III study. (a) Patients with at least three metastases (HR=0.71; P=0.037). (b) Patients with visceral-dominant disease (P=0.145) 16,24. HR, hazard ratio; Q3W, every 3 weeks.